Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have been given a consensus recommendation of “Moderate Buy” by the seven brokerages that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $11.17.

Several equities research analysts have issued reports on the stock. Leerink Partners downgraded shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $5.00 to $4.00 in a research note on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. D. Boral Capital reiterated a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Finally, Jefferies Financial Group boosted their price objective on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Monday, February 10th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Rock Springs Capital Management LP boosted its stake in shares of Compass Therapeutics by 2.7% in the fourth quarter. Rock Springs Capital Management LP now owns 5,779,575 shares of the company’s stock valued at $8,380,000 after purchasing an additional 150,336 shares during the period. Blue Owl Capital Holdings LP boosted its stake in shares of Compass Therapeutics by 2.6% in the fourth quarter. Blue Owl Capital Holdings LP now owns 2,954,712 shares of the company’s stock valued at $4,284,000 after purchasing an additional 75,000 shares during the period. Geode Capital Management LLC boosted its stake in shares of Compass Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 2,334,171 shares of the company’s stock valued at $3,386,000 after purchasing an additional 24,393 shares during the period. SG Americas Securities LLC boosted its stake in shares of Compass Therapeutics by 921.6% in the fourth quarter. SG Americas Securities LLC now owns 395,017 shares of the company’s stock valued at $573,000 after purchasing an additional 356,352 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Compass Therapeutics by 25.2% in the fourth quarter. Renaissance Technologies LLC now owns 278,600 shares of the company’s stock valued at $404,000 after purchasing an additional 56,000 shares during the period. 68.43% of the stock is currently owned by hedge funds and other institutional investors.

Compass Therapeutics Stock Performance

Compass Therapeutics stock opened at $3.38 on Tuesday. The company has a market cap of $465.05 million, a price-to-earnings ratio of -9.13 and a beta of 1.17. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $4.08. The firm has a 50 day moving average price of $2.28 and a 200 day moving average price of $1.81.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.